Vnitr Lek 1998, 44(6):332-335

[Ramipril in the treatment of moderate to moderately severe hypertension. A multicenter open study].

J Spinar, J Vítovec
II. interní klinika FN U sv. Anny LF MU, Brno.

A twelve-week open trial investigating the effect and tolerance of ramipril in 685 patients with mild to moderate hypertension in 88 clinics mostly of general practitioners (list with the author). The antihypertensive effect was investigated after 4, 8 and 12 weeks. The trial was terminated consistent with the protocol by 501 (73.1%) patients, 36 (5.3%) were eliminated early and in 148 (21.6%) the prescribed protocol was not respected. 413 patients (82.4%) terminated the trial on monotherapy, the remaining 88 (17.6%) had combined treatment from the 8th week onwards. When the trial with monotherapy was terminated the drop of blood pressure was more marked already during the 4th week and this trend proceeded during the 8th and 12th week, while in patients who had combined treatment from the 8th week the authors did not observe a drop of the blood pressure between the 4th and 8th week. The investigated laboratory indicators displayed insignificant changes within the range of normal values. The preparation was well tolerated, the total number of undesirable effects was 11% (three patients discontinued because of a cough). The effectiveness was evaluated by the attending physician as very good in 88%, the tolerance in 97%.

Keywords: Angiotensin-Converting Enzyme Inhibitors, adverse effects, ; Antihypertensive Agents, adverse effects, ; Blood Pressure, drug effects, ; Female; Humans; Hypertension, drug therapy, ; Male; Middle Aged; Ramipril, adverse effects,

Published: June 1, 1998  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Spinar J, Vítovec J. [Ramipril in the treatment of moderate to moderately severe hypertension. A multicenter open study]. Vnitr Lek. 1998;44(6):332-335.
Download citation




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.